The lifetime risk of undergoing surgery for incontinence or vaginal prolapsein the United States is nearly one in 11. As our population ages and lifeexpectancies increase, a greater number of women will present with pelvicfloor and voiding disorders. Because of this, there is significant interestin using evidence-based research to assess current diagnostic tools in theevaluation of stress urinary incontinence (SUI), as well as new potentialtreatments.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.